Gnosis to announce ibSium clinical results at UEG Week

UEG Week will be hosted on United European Gastroenterology's interactive congress platform, enabling live interaction with experts

Gnosis by Lesaffre will be exhibiting its latest clinical results at the Virtual Week 2020 organized by UEG (United European Gastroenterology) from October 11th to 13th. The results reinforce the efficacy of IbSium to alleviate gastrointestinal symptoms and improve quality of life.

IbSium is Gnosis’s patented probiotic yeast S. cerevisiae CNCM I-3856. UEG Week represents an opportunity to learn more about one of the most documented probiotic for a daily and complete digestive comfort.

“Saccharomyces cerevisiae CNCM I-3856 in IBS predominant constipation: a randomized, double-blind, placebo-controlled, multicentre clinical trial” is the title of the poster that will be held by Arnaud Bourreille, Gastroenterologist at the Institute for Digestive Tract Diseases.

Interested readers can register at the following link:

Featured Companies

Gnosis by Lesaffre (more information, website)